Publications
Number
Publication
Language
Rare diseases – Progress in diagnosis and therapy
Although each individual rare disease is obviously a rare occurrence, a relatively large number of people are affected by rare diseases since some 8,000 of these are already known. In Switzerland, for example, this concerns some 580,000 people – the same as the number of people suffering from diabetes in this country. In addition to an interview with a doctor and a profile of a sufferer, the brochure addresses the framework conditions for the development of drugs to combat rare diseases and, taking a few examples of rare diseases such as Niemann-Pick, hairy cell leukaemia and porphyria, shows where progress has been made and where the need for further research exists. The brochure was produced in collaboration with ProRaris – the Swiss Alliance for Rare Diseases.
Rare diseases – Progress in diagnosis and therapy
Health Panorama 2026/2027
Key facts and figures on the Swiss health and pharmaceutical landscape: Health Panorama assesses the current developments, provides relevant data and background information and offers food for thought for the political debate.
Health Panorama 2026/2027
Pharma Location Switzerland
MFN: Looking forward
MFN is already affecting Switzerland: companies are delaying or pausing launches. Low Swiss prices remain a strategic vulnerability beyond 2029, so Switzerland should prepare now.